01:19 PM EDT, 04/04/2024 (MT Newswires) -- Acumen Pharmaceuticals ( ABOS ) said Thursday that it has signed a collaboration agreement with healthcare manufacturing organization Lonza to develop and commercialize sabirnetug to treat Alzheimer's disease.

Under the terms of the deal, the drug substance will be produced by Lonza at its manufacturing facility in Portsmouth, New Hampshire, while Acumen will have access to Lonza's regulatory expertise, antibody manufacturing experience, and global manufacturing network.

Financial terms of the agreement were not disclosed.

Shares of the company rose 1% in recent trading.

Price: 3.95, Change: +0.04, Percent Change: +1.02